home.social

Search

1000 results for “eli”

  1. Eli Lilly gene-editing therapy cuts bad cholesterol by 62% in a Phase I trial of 35 participants

    Interim Phase I trial data shows a single dose of a gene-editing treatment significantly reduced LDL cholesterol levels in participants.

    newsnews.ai/article/eli-lilly-

  2. Elizabeth Taylor’s Fendi Baguettes Are Going Up For Auction at Christie’s

    The Fendi Baguette’s resurgence continues. Just last week, Fendi celebrated yet another re-edition of the beloved accessory, but…
    #France #FR #Europe #EU #Fendi #CelebrityStyle #fashion #homepage #lvmh
    europesays.com/france/26488/

  3. Elizabeth Taylor’s Rare Fendi Baguettes Are Heading to Auction at Christie’s

    2 min read Elizabeth Taylor collected diamonds, jewels, and apparently, very good Baguettes. Fendi Baguettes, that is. …
    #France #FR #Europe #EU #Fendi #content-type:News #contentId:77b5427c-3f01-4bab-be81-012955f0d285 #displayType:standardarticle #isSyndicated:false #locale:US #lvmh #read_time:2 #shortTitle:ElizabethTaylor’sFendiBaguettesHitChristie’s #subsection:CelebrityStyle
    europesays.com/france/26358/

  4. There's an update for tz. Get it so your app doesn't have to keep auto-updating 😄 hex.pm/packages/tz

  5. Elisa Estonia is deploying AI software to connect the backup batteries at its cell sites directly to the national energy grid. iottechnews.com/news/ai-turns-

  6. CyanView is a sneaky behind-the-scenes success story for Elixir powering the Super Bowl, Olympics as well as fashion runways. Daniil Popov hits the Goatmire stage to share their work using Elixir for desktop applications.
    goatmire.com/talk/the-beam-is-

  7. Eli Lilly is preparing a phase 2 trial for VERVE-102, a one-time gene editor acquired from Verve Therapeutics. The highest dose cut LDL cholesterol by 62% in patients, a reduction sustained for up to 18 months across 35 participants.

    The treatment permanently switches off PCSK9, a cholesterol-producing gene, using base editing that flips a single DNA letter without breaking the double helix.

    #news #health #medicine #cholesterol #GeneTherapy #GeneEditing

  8. Eli Lilly is preparing a phase 2 trial for VERVE-102, a one-time gene editor acquired from Verve Therapeutics. The highest dose cut LDL cholesterol by 62% in patients, a reduction sustained for up to 18 months across 35 participants.

    The treatment permanently switches off PCSK9, a cholesterol-producing gene, using base editing that flips a single DNA letter without breaking the double helix.

    #news #health #medicine #cholesterol #GeneTherapy #GeneEditing

  9. Eli Lilly is preparing a phase 2 trial for VERVE-102, a one-time gene editor acquired from Verve Therapeutics. The highest dose cut LDL cholesterol by 62% in patients, a reduction sustained for up to 18 months across 35 participants.

    The treatment permanently switches off PCSK9, a cholesterol-producing gene, using base editing that flips a single DNA letter without breaking the double helix.

    #news #health #medicine #cholesterol #GeneTherapy #GeneEditing

  10. Eli Lilly is preparing a phase 2 trial for VERVE-102, a one-time gene editor acquired from Verve Therapeutics. The highest dose cut LDL cholesterol by 62% in patients, a reduction sustained for up to 18 months across 35 participants.

    The treatment permanently switches off PCSK9, a cholesterol-producing gene, using base editing that flips a single DNA letter without breaking the double helix.

    #news #health #medicine #cholesterol #GeneTherapy #GeneEditing

  11. Eli Lilly is preparing a phase 2 trial for VERVE-102, a one-time gene editor acquired from Verve Therapeutics. The highest dose cut LDL cholesterol by 62% in patients, a reduction sustained for up to 18 months across 35 participants.

    The treatment permanently switches off PCSK9, a cholesterol-producing gene, using base editing that flips a single DNA letter without breaking the double helix.

    #news #health #medicine #cholesterol #GeneTherapy #GeneEditing